Business
Acadia Pharmaceuticals to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Cowen 42nd Annual Health Care Conference
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 2:50 p.m. Eastern Time.\n\nThe conference will be held virtually. A live webcast of Acadia’s presentation will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through April 9, 2022.\n\nAbout Acadia Pharmaceuticals\n\nAcadia is advancing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on treating psychosis in patients with dementia, the negative symptoms of schizophrenia and Rett syndrome. Our early-stage development efforts are focused on novel approaches to pain management, cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn and Twitter.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20220303005324/en/\n\nMedia Contact:\nAcadia Pharmaceuticals Inc.\nDeb Kazenelson\n(818) 395-3043\[email protected]\n\nInvestor Contact:\nAcadia Pharmaceuticals Inc.\nMark Johnson, CFA\n(858) 261-2771\[email protected]\n\n \n\nSource: Acadia Pharmaceuticals Inc.","length":3793,"tagName":"div"}]